U.S. Food and Drug Administration (FDA) · United States
FDA Healthcare Professional (HCP) Prescription Drug Promotion
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons.
21 CFR 202.1(e); FD&C Act § 502(n)
What is FDA Healthcare Professional (HCP) Prescription Drug Promotion?
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons. HCP-directed prescription drug promotional materials such as journal ads, sales aids, e-details and conference materials. This guide summarizes the supplied rule information for marketing review. Use the linked official source to confirm the current text, applicability and
general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-05-10
What does this rule require?
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons.
How can marketing teams comply?
HCP-directed prescription drug promotional materials such as journal ads, sales aids, e-details and conference materials.
What is FDA Healthcare Professional (HCP) Prescription Drug Promotion?
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug · pharma
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.
Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.
FDA's food labeling rules require a Nutrition Facts panel and other label elements and restrict nutrient and 'healthy' claims to foods meeting FDA criteria; the amended 'healthy' definition is effective April 28, 2025 with compliance required by Feb. 25, 2028.
Requires DTC Rx ads to present the major risk statement clearly, conspicuously and neutrally, to provide adequate provision for full prescribing information in broadcast, and to include a brief summary in print.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
Request a free compliance scan of your homepage and book a time with Warrant.